New generation of natural, effective, high-precision antimicrobials based on bacteriophages, to target and eliminate harmful bacteria
Harnessing the full potential of phages to develop novel antimicrobial compounds
Our Solution
MEDEA Biopharma is a lead discovery biopharmaceutical company developing new generation of high precision microorganisms to kill harmful bacteria by using bacteriophages. MEDEA Biopharma validates bacterial targets, discovers effective bacteriophages and enables scalable tailored applications in various industry fields.
Founded by lead scientists
Rüdiger Trojok, Dr. Elene Kakabadze, Giorgi Khubua and Alexander Skripnik founded MEDEA Biopharma in 2022 to revolutionize bacterial infection treatment and solve the antibiotic resistance issue.
Rüdiger Trojok
Managing Director
Dr. Elene Kakabadze
Chief Scientific Officer
Giorgi Khubua
Managing Director
Our industries
Potential to tackle multiple fields by personalized bacteriophages of MEDEA Biopharma with different application modalities
Human Health
Personalized bacteriophages in infectious diseases to kill AMR bacteria & reduce antibiotics.
Cosmetics
Personalized cosmetics with safe, effective bacteriophages to kill harmful bacteria.
Food Safety
Bacteriophages as prophylactic antimicrobials supplementing antibiotics in food chain.
Agriculture
Bacteriophages as antimicrobials supplementing antibiotics in agriculture chain.
Backed By
© Urheberrecht. Alle Rechte vorbehalten.